Krystal Biotech, Inc. - COMMON STOCK (KRYS) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2017 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
KRYS on Nasdaq
Shares outstanding
29,067,614
Price per share
$291.93
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
16,735,124
Total reported value
$4,124,917,275
% of total 13F portfolios
0.01%
Share change
+197,988
Value change
+$53,623,753
Number of holders
253
Price from insider filings
$291.93
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Krystal Biotech, Inc. - COMMON STOCK (KRYS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
STATE STREET CORP 4.4% $218,154,766 1,278,975 STATE STREET CORPORATION 31 Dec 2024

As of 31 Dec 2025, 253 institutional investors reported holding 16,735,124 shares of Krystal Biotech, Inc. - COMMON STOCK (KRYS). This represents 58% of the company’s total 29,067,614 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Krystal Biotech, Inc. - COMMON STOCK (KRYS) together control 50% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 14% 3,937,817 +2.7% 0.02% $970,829,404
VANGUARD GROUP INC 9.6% 2,778,845 -0.48% 0.01% $685,096,446
STATE STREET CORP 4.6% 1,342,303 -3.8% 0.01% $330,931,382
Soleus Capital Management, L.P. 3.2% 941,059 -7.6% 9.8% $232,008,686
Capital World Investors 2.8% 809,500 +0.03% 0.03% $199,574,130
GEODE CAPITAL MANAGEMENT, LLC 2.1% 611,878 +0.1% 0.01% $150,878,011
DIMENSIONAL FUND ADVISORS LP 1.7% 492,968 -7.7% 0.03% $121,538,226
Frazier Life Sciences Management, L.P. 1.7% 488,460 -29% 3.2% $120,424,928
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 1.3% 376,340 +152% 0.26% $92,782,864
GOLDMAN SACHS GROUP INC 1% 293,525 -16% 0.01% $72,365,654
NORGES BANK 0.98% 284,573 0.01% $70,158,627
FIRST TRUST ADVISORS LP 0.84% 245,276 -1.3% 0.04% $60,470,345
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.84% 242,774 -0.04% 0.01% $59,853,502
MORGAN STANLEY 0.76% 221,481 -5.6% 0% $54,604,696
Nuveen, LLC 0.65% 189,094 -4.2% 0.01% $46,619,235
MARSHALL WACE, LLP 0.63% 183,754 +42% 0.04% $45,302,711
PRINCIPAL FINANCIAL GROUP INC 0.57% 165,074 +16% 0.02% $40,697,345
UBS Group AG 0.55% 159,595 +23% 0.01% $39,346,551
Pictet Asset Management Holding SA 0.54% 156,568 -20% 0.04% $38,600,275
Bank of New York Mellon Corp 0.52% 151,313 -2.7% 0.01% $37,304,704
JPMORGAN CHASE & CO 0.46% 134,624 -8% 0% $33,190,200
FRANKLIN RESOURCES INC 0.43% 125,675 +533% 0.01% $30,983,914
Handelsbanken Fonder AB 0.36% 105,800 +58% 0.08% $26,084,000
VOYA INVESTMENT MANAGEMENT LLC 0.36% 103,261 +10% 0.03% $25,457,967
TimesSquare Capital Management, LLC 0.34% 97,400 -18% 0.36% $24,012,996

Institutional Holders of Krystal Biotech, Inc. - COMMON STOCK (KRYS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 16,735,124 $4,124,917,275 +$53,623,753 $246.54 253
2025 Q3 27,965,722 $4,936,825,964 +$84,621,791 $176.53 281
2025 Q2 27,659,439 $3,802,977,476 -$846,440 $137.46 274
2025 Q1 27,342,861 $4,929,918,497 -$51,223,771 $180.30 298
2024 Q4 27,774,030 $4,351,782,009 -$92,533,890 $156.66 264
2024 Q3 28,280,954 $5,147,915,246 -$55,463,849 $182.03 281
2024 Q2 28,529,838 $5,239,051,095 +$658,436,118 $183.64 245
2024 Q1 25,223,190 $4,487,798,716 +$175,442,652 $177.93 233
2023 Q4 24,418,337 $3,029,453,570 +$42,716,131 $124.06 194
2023 Q3 23,797,985 $2,760,663,293 +$92,606,023 $116.00 187
2023 Q2 23,039,160 $2,704,675,917 +$256,730,169 $117.40 182
2023 Q1 20,979,177 $1,678,957,589 +$9,326,151 $80.06 159
2022 Q4 20,961,146 $1,660,575,264 -$15,716,124 $79.22 153
2022 Q3 20,879,536 $1,455,390,527 +$2,509,281 $69.70 141
2022 Q2 20,782,487 $1,364,495,044 +$17,501,639 $65.66 129
2022 Q1 20,551,109 $1,367,525,309 +$24,889,158 $66.54 129
2021 Q4 19,309,579 $1,350,723,574 +$209,084,528 $69.95 135
2021 Q3 16,287,424 $850,358,590 -$12,114,445 $52.21 112
2021 Q2 16,400,636 $1,115,239,700 -$7,228,383 $68.00 113
2021 Q1 16,474,358 $1,268,577,569 +$201,515,888 $77.04 113
2020 Q4 13,913,023 $835,272,340 -$16,214,267 $60.00 107
2020 Q3 14,383,109 $619,123,442 +$11,279,105 $43.05 98
2020 Q2 14,124,381 $585,026,548 +$106,373,347 $41.42 108
2020 Q1 11,507,819 $497,600,700 -$9,385,943 $43.24 88
2019 Q4 11,391,925 $630,888,478 +$15,766,941 $55.38 89
2019 Q3 11,182,639 $388,328,616 +$48,273,351 $34.73 83
2019 Q2 9,765,134 $393,197,420 +$130,560,730 $40.27 75
2019 Q1 6,652,555 $218,869,000 +$15,470,940 $32.90 56
2018 Q4 6,208,589 $129,016,000 +$73,086,744 $20.78 45
2018 Q3 2,717,290 $47,597,000 +$6,006,830 $17.58 21
2018 Q2 2,390,244 $35,543,000 -$7,828,421 $14.87 16
2018 Q1 3,076,255 $31,040,000 -$1,629,988 $10.09 12
2017 Q4 3,236,349 $34,047,000 +$1,027,245 $10.52 13
2017 Q3 3,142,571 $31,331,000 +$31,331,000 $9.97 13